Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-02-24 M&A Activity
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca acquires CinCor for cardiorenal asset
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 0330R' and is dated February 24, 2023, detailing the completion of the acquisition of CinCor Pharma. It contains standard regulatory boilerplate language at the end, referencing RNS, the London Stock Exchange, and the Financial Conduct Authority. This structure is characteristic of a regulatory news service announcement. Since the content is a specific corporate action announcement (M&A completion) that is not a standard periodic report (like 10-K or IR) or a specific announcement type like Director's Dealing or Dividend Notice, and it is clearly distributed via the RNS system, the most appropriate classification is the general regulatory announcement category, RNS. The document length is substantial (12,270 chars), but its primary function is to disseminate time-sensitive corporate news via the official channel.
2023-02-24 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a gift of shares to charity by the CFO. The content focuses on insider shareholding changes and notifications under EU Market Abuse Regulation. It does not contain financial statements, earnings data, or management discussion. The document length is 4392 characters, which is relatively short and focused on a specific insider transaction. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2023-02-24 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification disseminated via RNS (RNS Number : 9849Q) concerning a 'Transaction by Person Discharging Managerial Responsibilities'. Specifically, it details the gift of American Depositary Shares (ADSs) by the Chief Financial Officer, Aradhana Sarin, to charity. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2023-02-24 English
SC TO-T/A Filing
M&A Activity Classification · 95% confidence The document is titled 'Schedule TO' and is filed under Rule 14d-100, which pertains to tender offer statements under the Securities Exchange Act of 1934. It is an Amendment No. 3 to a Schedule TO filed previously. The content discusses a tender offer by AstraZeneca entities to purchase shares of CinCor Pharma, Inc., including details about the offer expiration, shares tendered, acceptance, and the expected merger closing. It also mentions the delisting of shares post-merger. The Schedule TO is a regulatory filing specifically related to tender offers and takeover bids. According to the filing definitions, documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). The document is not a full merger proxy statement or tender offer form (which would be under MA), but an amendment to a tender offer statement, which fits best under M&A Activity. The document length (6890 characters) and detailed content confirm it is the filing itself, not just an announcement. Therefore, the correct classification is 'TAR' with high confidence.
2023-02-24 English
ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces a license agreement with KYM Biosciences for the drug CMG901, including financial terms and strategic details. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, management report, or regulatory certification. It is an announcement of a corporate transaction (license agreement) related to development and commercialization of a drug. This fits best under Capital/Financing Update (CAP) as it involves a significant licensing deal with upfront payments, milestones, and royalties, which are financing-related activities. The document length (7703 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive update on a capital-related transaction.
2023-02-23 English
AstraZeneca PLC;AstraZeneca Finance LLC - Supplementary Prospectus
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "PROSPECTUS SUPPLEMENT DATED 21 FEBRUARY 2023 TO THE BASE PROSPECTUS DATED 15 JUNE 2022". It discusses the Programme established under medium-term note regulations and is approved by the Financial Conduct Authority (FCA) under the UK Prospectus Regulation. The purpose of the supplement is to incorporate by reference parts of the company's Annual Report and update disclosures related to the Programme. A Prospectus Supplement is a key document used in capital raising and debt issuance activities, which falls under the category of financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-02-23 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.